Additionally, however, utilizing tesaglitazar provided an opportunity to test whether delivery of a PPARα/γ dual agonist to macrophages was sufficient to improve metabolic outcomes in a murine model of obesity. This evidence concerns the gene PPARA and obesity disorder.